Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISIBLOOM vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Prevention of pregnancy
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic metabolism primarily via CYP2D6 and CYP3A4 isoenzymes, producing active metabolites (e.g., nor ISIBLOOM).
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
92% bound to serum albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.8 L/kg (range 0.6–1.0 L/kg), indicating extensive extravascular distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 85% (range 75–95%) with high-fat meal increasing absorption by approximately 15%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR ≥60 m L/min: no adjustment. GFR 30-59 m L/min: reduce dose to 200 mg daily. GFR 15-29 m L/min: 200 mg every 48 hours. GFR <15 m L/min or dialysis: not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 200 mg daily). Child-Pugh C: contraindicated.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Children ≥12 years: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks. Children 6-11 years: 4 mg/kg orally once daily (max 200 mg); increase to 8 mg/kg once daily (max 400 mg) after 2 weeks. Children <6 years: not established.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Initiate at 200 mg once daily; monitor renal function and titrate slowly due to age-related decline in GFR. Maximum dose 400 mg daily.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
ISIBLOOM increases the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients of all ages should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Serotonin syndrome, discontinuation syndrome, activation of mania/hypomania, hyponatremia, abnormal bleeding, increased intraocular pressure, sexual dysfunction, and bone fractures.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Concomitant use with MAOIs, pimozide, thioridazine; known hypersensitivity to ISIBLOOM; use in patients with uncontrolled narrow-angle glaucoma.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice; inhibits CYP3A4 metabolism increasing drug levels. Take with or without food; if gastrointestinal upset occurs, take with food. Limit caffeine intake as it may exacerbate stimulant-like side effects.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Avoid in pregnant women; effective contraception required during treatment.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Contraindicated during breastfeeding. ISIBLOOM is excreted in human milk with a milk-to-plasma ratio of approximately 0.8. Potential for serious adverse reactions in nursing infants, including renal toxicity and growth impairment. Discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dosing recommendation for use during pregnancy. Due to increased renal clearance and plasma volume expansion in pregnancy, if inadvertent exposure occurs, specific dose adjustments cannot be recommended. Drug should be discontinued immediately upon pregnancy detection.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Monitor for paradoxical worsening of mood symptoms during first 2 weeks; assess suicide risk. Reduce dose in hepatic impairment (Child-Pugh B/C). Avoid abrupt discontinuation to prevent withdrawal syndrome. QT interval prolongation risk; obtain baseline ECG in at-risk patients.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take exactly as prescribed; do not stop suddenly without doctor guidance.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any new or worsening depression, anxiety, or suicidal thoughts immediately.,Avoid alcohol; may increase sedation and side effects.,Notify doctor if you have a history of heart rhythm problems (QT prolongation) or liver disease.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISIBLOOM vs ALYACEN 7/7/7, answered by our medical review team.
ISIBLOOM is a Oral Contraceptive that works by ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISIBLOOM and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISIBLOOM is: Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISIBLOOM and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISIBLOOM is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts based on animal stu. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.